US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.18 against a street estimate of 0.03 — a beat of 500.0%.
Analysts rate AtriCure Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $51.67.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.95% |
| Wellington Management Company LLP | 6.87% |
| AllianceBernstein L.P. | 6.41% |
| Hood River Capital Management LLC | 6.13% |
| Vanguard Portfolio Management, LLC | 5.31% |
| Vanguard Capital Management, LLC | 4.24% |
| Delaware Management Holdings Inc | 3.55% |
| The Goldman Sachs Group Inc | 3.28% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ATRICURE, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q2 2026: $153.6 million (up 12.8% vs. $136.1 million Q2 2025); H1 2026: $294.9 mill | 2026-07-27 |
| Results announced · Q3 2026 ATRICURE, INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $153.6 million (12.8% year-over-year growth; 12.4% constant currency) | 2026-07-23 |
| Board / officer change · Q2 2026 ATRICURE, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Stock Incentive Plan expansion: 2023 Stock Incentive Plan share pool increased from 4,500,000 t | 2026-05-19 |
| Quarterly report · Q1 2026 ATRICURE, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Revenue Q1 2026: $141,249 thousand vs. $123,620 thousand Q1 2025 (14.3% increase) • Gr | 2026-05-06 |
| Results announced · Q2 2026 ATRICURE INC. - Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 worldwide revenue: $141.2 million — up 14.3% year-over-year (12.8% cons | 2026-05-05 |
| Proxy statement · Q2 2026 ATRICURE, INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Michael H. Carrel (President and CEO) total compensation for 2025: $7,234,797 - This rep | 2026-04-06 |
| Annual report FY2025 ATRICURE, INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: AtriCure, Inc. (Ticker: ATRC, NASDAQ) • Headquarters: Mason, Ohi | 2026-02-19 |
| Results announced · Q1 2026 ATRICURE, INC. – FINANCIAL SUMMARY HEADLINE NUMBERS • Q4 2025 worldwide revenue: $140.5 million (+13.1% year-over-year) • Full Year 2025 worldwide r | 2026-02-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AtriCure Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.